<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477893</url>
  </required_header>
  <id_info>
    <org_study_id>HUM 04-078</org_study_id>
    <nct_id>NCT00477893</nct_id>
  </id_info>
  <brief_title>Danish Multicenter Study of Adalimumab in Spondyloarthritis</brief_title>
  <acronym>DANISH</acronym>
  <official_title>Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spondyloarthropathies (SpA) are often diagnosed with a considerable delay (often 8-10 years
      from symptom onset), because the available clinical, biochemical and radiological methods are
      not sufficiently sensitive. TNF-a antagonists have recently been introduced for treatment of
      SpA, and current data indicate a higher efficacy than previously available therapies. The
      improved treatment options have increased the need for improved methods for diagnosis,
      monitoring and prognostication of these diseases, so that the efficient therapies can be
      initiated at the optimal time point and monitored optimally. Magnetic resonance imaging (MRI)
      and a number of biomarkers are promising, but not yet sufficiently studied, methods for this.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in BASDAI of 20 mm or 50%</measure>
    <time_frame>12-24 weeks of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study</description>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of spondyloarthritis according to the European Spondyloarthritis Study Group
             (ESSG) criteria

          2. Clinical active disease, defined as a BASDAI score &gt; 4 despite concurrent NSAID
             therapy

          3. Presence of sacroiliitis on conventional radiography or MRI.

          4. Among other issues: Age &gt;18 years; adequate birth control; no contraindications for
             anti-TNFa-therapy, no previous TNFa-antagonists

        Exclusion Criteria:

          1. Previous TNFα inhibitor therapy

          2. Treatment with disease modifying anti-rheumatic drugs within 4 weeks before screening

          3. Oral, intraarticular, intramuscular or intravenous glucocorticoid within 4 weeks
             before screening

          4. Pregnancy or lactation

          5. HIV, hepatitis B or C, tuberculosis, other infections

          6. Malignancies

          7. Other serious concomitant diseases (uncontrolled/severe kidney, liver, haematological,
             gastrointestinal, endocrine, cardiovascular, pulmonary, neurological ore cerebral
             disease (including demyelinating disease)

          8. Contraindications to anti-TNFa-therapy

          9. Contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge Juul Sørensen, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Rheumatology, Glostrup University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne Juhl Pedersen, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Rheumatology, Glostrup University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikkel Ostergaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Rheumatology, Glostrup University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiology, Aabenraa Hospital</name>
      <address>
        <city>Aabenraa</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiology, Herlev University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Gentofte University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Glostrup University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Herlev University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Hvidovre University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Christian X´s Hospital of Rheumatic Diseases</name>
      <address>
        <city>Graasten</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Hørsholm Hospital</name>
      <address>
        <city>Hørsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiology, Vejle Hospital,</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiology, Århus University Hospital</name>
      <address>
        <city>Århus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>MOstergaard</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

